If your dog does not need a prescription medication or you cannot take him to his regular veterinarian, a natural treatment ...

Bausch Health's Aplenzin could revolutionize TRD care, addressing a $3B market opportunity while aiding BHC stock's financial ...

Bausch + Lomb (NYSE:BLCO – Get Free Report) had its price objective lowered by stock analysts at Stifel Nicolaus from $17.00 ...

NEW YORK CITY, NY / ACCESS Newswire / April 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Medical Devices Market Size Medical Devices Market Share Leading companies in the medical devices market include Johnson & Johnson S ...

Bausch + Lomb Co. (NYSE:BLCO – Get Free Report)’s stock price reached a new 52-week low during trading on Thursday after ...

The U.S. Food and Drug Administration has once again declined to approve Aldeyra Therapeutics treatment for dry eye disease, ...

NEW YORK CITY, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Miebo produced substantial symptom relief in patients with dry eye disease during the first day and succeeding weeks of ...

Bausch Health's gastroenterology business, Salix Pharmaceuticals, recognizes the complexities of irritable bowel syndrome (IBS) and seeks to make a difference in how the condition is perceived, ...

Detailed price information for Bausch Lomb Corporation (BLCO-T) from The Globe and Mail including charting and trades.

Detailed price information for Bausch Health Companies Inc (BHC-T) from The Globe and Mail including charting and trades.